What if you could kill cancer cells by inhibiting the enzyme that enables their uncontrolled division?
Our science, expertise and readiness to bring our novel investigational telomerase inhibitor to market could transform the treatment landscape of blood cancers, which drives our single-minded urgency to deliver innovative therapies to patients.
Our pipeline
We are exploring the broad potential of telomerase inhibition across multiple hematologic malignancies.
*TELOMERE is expected to begin after an appropriate dose for single agent imetelstat in AML has been identified in the IMpress study.
We are currently conducting two imetelstat Phase 3 clinical trials with registrational intent:
Imetelstat: our first-in-class investigational telomerase inhibitor
Our novel investigational telomerase inhibitor harnesses Nobel Prize-winning science that has the potential to suppress the uncontrolled proliferation of malignant stem cells, which we believe are the source of disease in blood cancers.
Publications
Non-clinical and clinical studies have generated strong evidence of the potential disease-modifying activity and clinical benefit of imetelstat. There are more than 85 publications and presentations describing telomerase inhibition and imetelstat’s mechanism of action, efficacy, safety and potential.
Read more about our results:
Partnering
We plan to partner with patients, care partners, physicians and payers to provide safe, effective and innovative medications to fight blood cancers, with the potential to significantly enhance both length and quality of life over the long term.
Business development
As a late-stage biopharmaceutical company with deep experience in discovery and development, paired with growing commercial capabilities, Geron is preparing to bring our novel investigational telomerase inhibitor to market.
We remain interested in value-accreting strategic partnerships that have the potential to bring complementary capabilities and programs intended to realize the full potential of our first-in-class investigational telomerase inhibitor to address unmet medical needs on a global basis.
To contact our Business Development team, please send us an email.
busdev@geron.com
Scientific collaborators
Starting with our foundational research in telomere biology, Geron has embraced partnerships that can advance the scientific understanding of this field, at both a non-clinical and clinical level. As part of our pipeline expansion, we are exploring imetelstat’s potential in additional indications and in combination with current standard of care therapies through early-stage trials. We also have a discovery research program to identify a next generation telomerase inhibitor.
We invite you to discuss possible collaborations with us that could advance the further development of novel telomerase-based therapies or other possible, innovative approaches to the treatment of hematologic malignancies. For all inquiries, please email us.
info@geron.com
We are on a mission to extend and enhance lives
Discover more about our commitment to patients